Clinical Study | Office of Clinical Research

A Phase III Randomized Trial Comparing High Dose Interferon To Mk-3475 (Pembrolizumab) In Patients With High Risk Resected Melanoma.

Posted Date: May 15, 2019

Investigator: Rekha Chaudhary
Type of Study: Drug

the purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment with interferon alfa-2b. This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or wors

Criteria:

To Be Eligible To Participate, Patients Must Have Been Diagnosed With Melanoma, Which Although It Ha

Keywords:

Resected, Skin Cancer, S1404, Cancer, Melanoma

For More Information:

Uc Cancer Center
513-584-7698
kastla@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List